Verition Fund Management’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,000,000
| Closed | -$14.5M | – | 2235 |
|
|
2026
Q1 | $14.5M | Buy |
1,000,000
+350,438
| +54% | +$5.02M | 0.09% | 217 |
|
|
2025
Q4 | $9.25M | Buy |
649,562
+499,506
| +333% | +$4.91M | 0.04% | 508 |
|
|
2025
Q3 | $1.18M | Sell |
150,056
-1,364,995
| -90% | -$9.71M | ﹤0.01% | 2399 |
|
|
2025
Q2 | $8.68M | Buy |
1,515,051
+1,233,880
| +439% | +$7.96M | 0.04% | 611 |
|
|
2025
Q1 | $2.29M | Buy |
281,171
+153,414
| +120% | +$1.42M | 0.01% | 1475 |
|
|
2024
Q4 | $1.2M | Buy |
127,757
+105,333
| +470% | +$1.09M | ﹤0.01% | 1926 |
|
|
2024
Q3 | $239K | Buy |
22,424
+225
| +1% | +$2.45K | ﹤0.01% | 2774 |
|
|
2024
Q2 | $220K | Buy |
22,199
+3,432
| +18% | +$35.2K | ﹤0.01% | 2534 |
|
|
2024
Q1 | $221K | Buy |
+18,767
| New | +$240K | ﹤0.01% | 2450 |
|
|
2023
Q2 | – | Sell |
-26,859
| Closed | -$298K | – | 2312 |
|
|
2023
Q1 | $298K | Buy |
+26,859
| New | +$331K | ﹤0.01% | 1528 |
|
|
2020
Q1 | – | Sell |
-12,750
| Closed | -$124K | – | 770 |
|
|
2019
Q4 | $124K | Sell |
12,750
-64,494
| -83% | -$590K | ﹤0.01% | 1004 |
|
|
2019
Q3 | $619K | Sell |
77,244
-3,652
| -5% | -$39.6K | 0.02% | 557 |
|
|
2019
Q2 | $1.01M | Buy |
+80,896
| New | +$1.03M | 0.03% | 434 |
|
|
2015
Q2 | – | Sell |
-22,494
| Closed | -$245K | – | 652 |
|
|
2015
Q1 | $245K | Buy |
+22,494
| New | +$198K | 0.03% | 263 |
|
Other funds holding FOLD
Verition Fund Management's FOLD Position: Q2 2026 in Review
Verition Fund Management sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 1,000,000 shares — an estimated $14.5M sold.
Verition Fund Management first reported a position in FOLD in Q1 2015 and held it in 14 quarters. The position peaked at $14.5M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- Verition Fund Management reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Verition Fund Management sold 1,000,000 Amicus Therapeutics shares in Q2 2026, an estimated $14.5M.
- Verition Fund Management first reported a position in Amicus Therapeutics in Q1 2015 and held it in 14 quarters.
- Verition Fund Management's Amicus Therapeutics position peaked at $14.5M in Q1 2026.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.